Cochlear Ltd
Company Profile
Business description
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Contact
1 University Avenue
Macquarie University
SydneyNSW2109
AUST: +61 294286555
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
4,749
Cochlear Ltd News & Analysis
stocks
Reporting season was stronger than share prices suggest
markets
The grass is always greener: Rethinking Australian vs global equities
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.50 | 15.50 | -0.17% |
| CAC 40 | 7,827.63 | 5.25 | -0.07% |
| DAX 40 | 25,259.90 | 17.78 | -0.07% |
| Dow JONES (US) | 51,716.69 | 133.86 | -0.26% |
| FTSE 100 | 10,650.33 | 5.95 | -0.06% |
| HKSE | 24,345.22 | 74.02 | 0.30% |
| NASDAQ | 27,185.11 | 60.80 | -0.22% |
| Nikkei 225 | 67,777.52 | 1,253.40 | -1.82% |
| NZX 50 Index | 13,749.60 | 78.02 | -0.56% |
| S&P 500 | 7,803.32 | 3.92 | -0.05% |
| S&P/ASX 200 | 8,783.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,800.86 | 3.62 | 0.10% |